Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Payables (2023 - 2025)

Monte Rosa Therapeutics (GLUE) has 3 years of Payables data on record, last reported at $14.5 million in Q3 2025.

  • For Q3 2025, Payables fell 3.91% year-over-year to $14.5 million; the TTM value through Sep 2025 reached $14.5 million, down 3.91%, while the annual FY2024 figure was $18.8 million, 68.45% up from the prior year.
  • Payables reached $14.5 million in Q3 2025 per GLUE's latest filing, up from $13.8 million in the prior quarter.
  • Across five years, Payables topped out at $18.8 million in Q4 2024 and bottomed at $5.3 million in Q2 2023.
  • Average Payables over 3 years is $11.4 million, with a median of $11.2 million recorded in 2023.
  • Peak YoY movement for Payables: surged 174.53% in 2024, then dropped 3.91% in 2025.
  • A 3-year view of Payables shows it stood at $11.2 million in 2023, then soared by 68.45% to $18.8 million in 2024, then decreased by 22.76% to $14.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Payables were $14.5 million in Q3 2025, $13.8 million in Q2 2025, and $16.3 million in Q1 2025.